|
|
|
|
|
|
|
M T W Thu F |
|
25 June, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Join us at noon ET today for a roundtable discussion on the findings from our latest Endpoints 100 survey of C-suite executives. Lots on the table, including CEO optimism, MFN, the FDA and China. Hope to see you soon! |
|
|
|
Karen Weintraub |
Deputy Editor, Endpoints News
|
|
|
|
|
|
|
by Elizabeth Cairns
|
Nature Medicine has retracted a high-profile paperit published in February detailing the results of a China-based trial suggesting that cancer immunotherapy was more effective... | |
|
|
|
|
|
|
|
|
by Ayisha Sharma
|
Merck KGaA has said it is shopping for deals. And on Thursday, the German conglomerate revealed it will make its largest acquisition in a decade... | |
|
|
|
 |
|
|
|
by ENDPOINTS |
Plus news about Leyden Labs, Otsuka, Pfizer and Hutchmed. 🤝 Recordati licenses Ionis’ Alexander disease drug: The Italian company will be responsiblefor regulatory and... | |
|
|
|
 |
|
|
|
by Kyle LaHucik
|
Luke Miels made plans for a big cancer deal to grow GSK's small oncology portfolio before he began as CEO at the start of this... | |
|
|
|
|
|
|
